A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

Status:

Closed to Accrual

III

Phase

1st

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

ER+, HER2-

Investigational

Product

Abemaciclib (LY2835219

CDK4/6 Inhibitor (p.o.)

Treatment Arms

o Experimental: Abemaciclib + NSAI

o Placebo Comparator: Placebo + NSAI